Korean Lipolytic Products: A Practitioner's Guide to Selection and Use
Korean manufacturers have been producing pharmaceutical-grade lipolytic injectables for over two decades — longer than any other national market. The Korean aesthetic market's high volume, regulatory rigour, and clinical experimentation across multiple applications have produced a depth of lipolytic product knowledge embedded in Korean formulations that European manufacturers have not yet matched. For UK and EU practitioners, this translates to a choice of CE-marked, MFDS-approved DCA and PC/DCA products that offer pharmaceutical-grade quality at 30–50% lower wholesale cost than European alternatives.
DCA vs PC/DCA: Choosing the Right Lipolytic Agent for Your Patient
Two agents dominate injectable lipolytic practice: deoxycholic acid (DCA) as a single agent, and phosphatidylcholine combined with deoxycholic acid (PC/DCA) as a combination formulation. Both destroy subcutaneous fat cells, both produce the inflammatory clearance response that delivers the result, and both are available as CE-marked Korean formulations at Celmade. But they are not identical — and practitioners who understand the specific differences between them are better positioned to choose the right product for each clinical situation.
